Drug Development · global
Alpha-emitting radiopharmaceutical RYZ101 meets Phase 3 endpoint, offering new insights for neuroendocrine tumors progressing after lutetium-177 treatment
Patients whose disease continues to progress after prior radionuclide therapy may gain another treatment option. RYZ101 has met its primary progression-free survival endpoint, but the magnitude of benefit and detailed safety data have not yet been released, leaving key information needed to establish its clinical value.
For patients with gastroenteropancreatic neuroendocrine tumors whose disease progresses again after radionuclide therapy, maintaining disease control is a major treatment challenge. Bristol Myers Squibb (BMS) announced on October 12 that RYZ101, an alpha-particle radiopharmaceutical developed by its subsidiary RayzeBio, met the primary endpoint at a planned interim analysis of the Phase 3 ACTION-1 trial, providing new clinical research insights for these patients.
This global randomized trial enrolled patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) whose disease had progressed after lutetium-177 treatment. According to the company announcement and reporting by BioPharm International, RYZ101 significantly improved progression-free survival (PFS) as assessed by blinded independent central review—the time patients remain alive without their disease progressing. However, the announcement did not provide median PFS, a hazard ratio, or event rates, so the magnitude of the improvement cannot yet be determined.
The trial's comparator helps define the significance of this result. According to Targeted Oncology, the control group received the investigator's choice of high-dose or high-frequency long-acting somatostatin analogs, everolimus, or sunitinib. ACTION-1 uses an open-label design, meaning patients and physicians know the treatment assignments; the primary PFS endpoint is assessed by an independent central review blinded to those assignments to reduce assessment bias.
The study population also sets limits on the applicability of the results. Citing ClinicalTrials.gov data, OncLive reported that the trial enrolled 343 participants. Eligible patients had grade 1 or grade 2 GEP-NETs, a Ki-67 proliferation index of no more than 20%, and disease progression after prior lutetium-177 treatment. This means the results cannot be directly extended to all neuroendocrine tumors, particularly those with faster proliferation or patients who have not received lutetium-177 treatment.
RYZ101 delivers radiation therapy using alpha particles. This study examines whether another radiopharmaceutical can continue to control disease after lutetium-177 treatment. Meeting the primary endpoint supports further investigation of this approach, but improved PFS does not yet equate to longer overall survival. Participants will continue to receive care according to the trial protocol, and the study will continue to follow overall survival.
Assessing safety likewise requires complete data. The company said the observations were consistent with RYZ101's established safety profile, but detailed adverse events, their severity, and treatment discontinuations have not yet been disclosed. For patients who have already received radionuclide therapy, whether subsequent data clearly show the trade-off between efficacy and toxicity will influence the treatment's practical clinical value. Detailed efficacy and safety results are expected to be presented at a future medical meeting.
BMS plans to discuss subsequent regulatory submissions with the U.S. Food and Drug Administration (FDA), but has not provided a submission timeline. OncLive also reported that RYZ101 received FDA orphan drug designation for GEP-NETs in August 2026; this designation itself is not marketing approval. The Phase 3 result represents clear progress, while whether RYZ101 can become a treatment option remains to be determined by the complete trial results and regulatory review.